# MiMedx Group (MDXG) — Earnings

MDXG · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mdxg/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.10 |
| EPS estimate | −$0.05 |
| EPS surprise | −102.02% |
| Revenue surprise | +1.42% |
| Revenue | $64.4M |
| Revenue estimate | $63.5M |
| Reported | Jul 29, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1376339/000137633926000071/mdxg-20260630.htm) |

MiMedx reported Q2 2026 results on July 29, 2026. It posted a loss of $0.10 per share, wider than the expected $0.05 loss, a miss of 102.02%. Revenue was $64.4 million, 1.42% above the $63.5 million estimate. In Q2 2025, MiMedx earned $0.06 per share on revenue of $98.6 million, so revenue fell about 35% year over year.

The last two quarters broke a profitable run. After losses in all four quarters of 2022 and in Q1 2023, MiMedx broke even in Q2 2023 and earned a profit in every quarter from Q3 2023 through Q4 2025. Annual EPS was $0.32 in 2023, $0.28 in 2024 and $0.32 in 2025, while revenue grew from $321.5 million to $418.6 million. Revenue peaked here at $118.1 million in Q4 2025, then fell by half to $59.0 million in Q1 2026. MiMedx beat the EPS estimate in 13 of the last 20 quarters, but in only 4 of the last 8.

Q3 results came out between October 29 and November 2 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the company returns to a profit.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 29, 2026 | −$0.05 | −$0.10 | -102.02% | $63.5M | $64.4M |
| Q1 2026 | Apr 29, 2026 | −$0.03 | −$0.07 | -178.88% | $65.8M | $59.0M |
| Q4 2025 | Feb 25, 2026 | $0.09 | $0.10 | 13.25% | $106.8M | $118.1M |
| Q3 2025 | Oct 29, 2025 | $0.08 | $0.11 | 40.66% | $101.9M | $113.7M |
| Q2 2025 | Jul 30, 2025 | $0.05 | $0.06 | 14.29% | $90.6M | $98.6M |
| Q1 2025 | Apr 30, 2025 | $0.05 | $0.05 | -7.41% | $86.3M | $88.2M |
| Q4 2024 | Feb 26, 2025 | $0.07 | $0.05 | -30.56% | $89.4M | $92.9M |
| Q3 2024 | Oct 30, 2024 | $0.04 | $0.05 | 13.64% | $82.6M | $84.1M |
| Q2 2024 | Jul 31, 2024 | $0.08 | $0.12 | 60.00% | $89.0M | $87.2M |
| Q1 2024 | Apr 30, 2024 | $0.05 | $0.06 | 33.33% | $79.3M | $84.7M |
| Q4 2023 | Feb 28, 2024 | $0.07 | $0.32 | 344.44% | $85.1M | $86.8M |
| Q3 2023 | Oct 30, 2023 | $0.05 | $0.06 | 30.43% | $76.9M | $81.7M |
| Q2 2023 | Aug 1, 2023 | −$0.02 | $0.00 | 100.00% | $74.8M | $81.3M |
| Q1 2023 | May 2, 2023 | −$0.09 | −$0.06 | 30.80% | $64.3M | $71.7M |
| Q4 2022 | Feb 28, 2023 | −$0.04 | −$0.02 | 50.00% | $74.5M | $74.4M |
| Q3 2022 | Nov 2, 2022 | −$0.08 | −$0.09 | -16.13% | $66.7M | $67.7M |
| Q2 2022 | Aug 2, 2022 | −$0.06 | −$0.11 | -94.00% | $65.1M | $66.9M |
| Q1 2022 | May 3, 2022 | −$0.10 | −$0.11 | -10.00% | $54.1M | $58.9M |
| Q4 2021 | Feb 28, 2022 | −$0.03 | $0.01 | 130.03% | $63.7M | $67.4M |
| Q3 2021 | Nov 2, 2021 | −$0.08 | $0.02 | 128.88% | $60.3M | $63.1M |

## Frequently Asked Questions

### When did MiMedx Group (MDXG) last report earnings?

MiMedx Group last reported on Jul 29, 2026, covering fiscal Q2 2026.

### Did MDXG beat earnings estimates?

No. MiMedx Group reported EPS of −$0.10 for Q2 2026 against a −$0.05 estimate — a 102.02% miss.

### How much revenue did MDXG report last quarter?

MiMedx Group reported $64.4M in revenue for Q2 2026, against a consensus estimate of $63.5M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).